Search Results - "Roxana Mehran, MD"

Prosthetic Heart Valve Thrombosis by Dangas, George D., MD, PhD, Weitz, Jeffrey I., MD, Giustino, Gennaro, MD, Makkar, Raj, MD, Mehran, Roxana, MD

“…Abstract Although surgery was the mainstay of treatment for valvular heart disease, transcatheter valve therapies have grown exponentially over the past…”
Get full text

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease by Levine, Glenn N., MD, FACC, FAHA, Bates, Eric R., MD, FACC, FAHA, FSCAI, Bittl, John A., MD, FACC, Brindis, Ralph G., MD, MPH, MACC, FAHA, Fihn, Stephan D., MD, MPH, Fleisher, Lee A., MD, FACC, FAHA, Granger, Christopher B., MD, FACC, FAHA, Lange, Richard A., MD, MBA, FACC, Mack, Michael J., MD, FACC, Mauri, Laura, MD, MSc, FACC, FAHA, FSCAI, Mehran, Roxana, MD, FACC, FAHA, FSCAI, Mukherjee, Debabrata, MD, FACC, FAHA, FSCAI, Newby, L. Kristin, MD, MHS, FACC, FAHA, O’Gara, Patrick T., MD, FACC, FAHA, Sabatine, Marc S., MD, MPH, FACC, FAHA, Smith, Peter K., MD, FACC, Smith, Sidney C., MD, FACC, FAHA

Get full text

In-Stent Restenosis in the Drug-Eluting Stent Era by Dangas, George D., MD, Claessen, Bimmer E., MD, Caixeta, Adriano, MD, Sanidas, Elias A., MD, Mintz, Gary S., MD, Mehran, Roxana, MD

“…The introduction of the drug-eluting stent (DES) proved to be an important step forward in reducing rates of restenosis and target lesion revascularization…”
Get full text

Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention by Généreux, Philippe, MD, Giustino, Gennaro, MD, Witzenbichler, Bernhard, MD, Weisz, Giora, MD, Stuckey, Thomas D., MD, Rinaldi, Michael J., MD, Neumann, Franz-Josef, MD, Metzger, D. Christopher, MD, Henry, Timothy D., MD, Cox, David A., MD, Duffy, Peter L., MD, MMM, Mazzaferri, Ernest, MD, Yadav, Mayank, MD, Francese, Dominic P., MPH, Palmerini, Tullio, MD, Kirtane, Ajay J., MD, SM, Litherland, Claire, MS, Mehran, Roxana, MD, Stone, Gregg W., MD

“…Abstract Background The incidence, predictors, and prognostic impact of post-discharge bleeding (PDB) after percutaneous coronary intervention (PCI) with…”
Get full text

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study by Stone, Gregg W, Dr, Witzenbichler, Bernhard, MD, Weisz, Giora, MD, Rinaldi, Michael J, MD, Neumann, Franz-Josef, MD, Metzger, D Christopher, MD, Henry, Timothy D, MD, Cox, David A, MD, Duffy, Peter L, MD, Mazzaferri, Ernest, MD, Gurbel, Paul A, MD, Xu, Ke, PhD, Parise, Helen, MSc, Kirtane, Ajay J, MD, Brodie, Bruce R, MD, Mehran, Roxana, MD, Stuckey, Thomas D, MD

“…Summary Background The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation…”
Get full text

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer by Povsic, Thomas J., MD, PhD, Lawrence, Monica G., MD, Lincoff, A. Michael, MD, Mehran, Roxana, MD, Rusconi, Christopher P., PhD, Zelenkofske, Steven L., DO, Huang, Zhen, MS, Sailstad, Jeffrey, BS, Armstrong, Paul W., MD, Steg, P. Gabriel, MD, Bode, Christoph, MD, Becker, Richard C., MD, Alexander, John H., MD, MHS, Adkinson, N. Franklin, MD, Levinson, Arnold I., MD

“…Murine models of anaphylaxis have suggested that IgG antibody/allergen complexes interacting with Fcγ receptors on basophils and neutrophils release…”
Get full text

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI) by Gibson, C. Michael, MS, MD, Mehran, Roxana, MD, Bode, Christoph, MD, Halperin, Johnathan, MD, Verheugt, Freek, MD, Wildgoose, Peter, PhD, van Eickels, Martin, MD, Lip, Gregory Y.H., MD, Cohen, Marc, MD, Husted, Steen, MD, Peterson, Eric, MD, Fox, Keith, MD

“…Background Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary intervention (PCI) among patients with atrial fibrillation…”
Get full text

A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes by Mehran, Roxana, MD, Pocock, Stuart J., PhD, Nikolsky, Eugenia, MD, PhD, Clayton, Tim, MSc, Dangas, George D., MD, Kirtane, Ajay J., MD, Parise, Helen, ScD, Fahy, Martin, MSc, Manoukian, Steven V., MD, Feit, Frederick, MD, Ohman, Magnus E., MD, Witzenbichler, Bernard, MD, Guagliumi, Giulio, MD, Lansky, Alexandra J., MD, Stone, Gregg W., MD

“…Objectives The aim of this study was to develop a practical risk score to predict the risk and implications of major bleeding in acute coronary syndromes…”
Get full text

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention: Rationale and Design of the TWILIGHT Study by Baber, Usman, MD MS, Dangas, George, MD PhD, Cohen, David J., MD MSc, Gibson, C. Michael, MD, Mehta, Shamir, MD MSc, Angiolillo, Dominick, MD PhD, Pocock, Stuart, PhD, Krucoff, Mitchell W., MD, Kastrati, Adnan, MD, Ohman, E. Magnus, MD, Steg, Philippe Gabriel, MD, Badimon, Juan, PhD, Zafar, Urooj, PhD, Chandrasekhar, Jaya, MBBS, Sartori, Samantha, PhD, Aquino, Melissa, MS, Mehran, Roxana, MD

“…Abstract Background Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet increases bleeding after percutaneous coronary intervention (PCI)…”
Get full text

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease by Levine, Glenn N., MD, FACC, FAHA, Bates, Eric R., MD, FACC, FAHA, FSCAI, Bittl, John A., MD, FACC, Brindis, Ralph G., MD, MPH, MACC, FAHA, Fihn, Stephan D., MD, MPH, Fleisher, Lee A., MD, FACC, FAHA, Granger, Christopher B., MD, FACC, FAHA, Lange, Richard A., MD, MBA, FACC, Mack, Michael J., MD, FACC, Mauri, Laura, MD, MSc, FACC, FAHA, FSCAI, Mehran, Roxana, MD, FACC, FAHA, FSCAI, Mukherjee, Debabrata, MD, FACC, FAHA, FSCAI, Newby, L. Kristin, MD, MHS, FACC, FAHA, O'Gara, Patrick T., MD, FACC, FAHA, Sabatine, Marc S., MD, MPH, FACC, FAHA, Smith, Peter K., MD, FACC, Smith, Sidney C., MD, FACC, FAHA, Halperin, Jonathan L., MD, FACC, FAHA, Al-Khatib, Sana M., MD, MHS, FACC, FAHA, Birtcher, Kim K., PharmD, MS, AACC, Bozkurt, Biykem, MD, PhD, FACC, FAHA, Cigarroa, Joaquin E., MD, FACC, Curtis, Lesley H., PhD, FAHA, Gentile, Federico, MD, FACC, Gidding, Samuel, MD, FAHA, Hlatky, Mark A., MD, FACC, FAHA, Ikonomidis, John S., MD, PhD, FAHA, Joglar, José A., MD, FACC, FAHA, Pressler, Susan J., PhD, RN, FAHA, Wijeysundera, Duminda N., MD, PhD

Get full text

Short-Term Rosuvastatin Therapy for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Diabetes and Chronic Kidney Disease by Han, Yaling, MD, PhD, Zhu, Guoying, MD, Han, Lixian, MD, Hou, Fengxia, MD, Huang, Weijian, MD, Liu, Huiliang, MD, Gan, Jihong, MD, Jiang, Tiemin, MD, Li, Xiaoyan, MD, Wang, Wei, MD, Ding, Shifang, MD, Jia, Shaobin, MD, Shen, Weifeng, MD, Wang, Dongmei, MD, Sun, Ling, MD, Qiu, Jian, MD, Wang, Xiaozeng, MD, Li, Yi, MD, Deng, Jie, MD, Li, Jing, MD, Xu, Kai, MD, Xu, Bo, MBBS, Mehran, Roxana, MD, Huo, Yong, MD

“…Objectives This study sought to evaluate the safety and efficacy of rosuvastatin in preventing contrast-induced acute kidney injury (CI-AKI) in patients with…”
Get full text

Reply by Giustino, Gennaro, MD, Mehran, Roxana, MD

Get full text

Risk scores in acute coronary syndrome and percutaneous coronary intervention: A review by Bawamia, Bilal, MB, BS, Mehran, Roxana, MD, Qiu, Weiliang, PhD, Kunadian, Vijay, MB, BS, MD, FRCP

“…Patients with acute coronary syndrome (ACS) need to be risk stratified to deliver the most appropriate therapy. The GRACE and TIMI risk scores have penetrated…”
Get full text

Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus by Kedhi, Elvin, MD, PhD, Généreux, Philippe, MD, Palmerini, Tullio, MD, McAndrew, Thomas C., MS, Parise, Helen, ScD, Mehran, Roxana, MD, Dangas, George D., MD, PhD, Stone, Gregg W., MD

“…Objectives The aim of this study was to investigate whether baseline lesion complexity affects drug-eluting stent (DES) outcomes according to diabetic status…”
Get full text

Relation of Baseline Hemoglobin Levels and Adverse Events in Patients with Acute Coronary Syndromes (from the ACUITY and HORIZONS-AMI Trials) by Brener, Sorin J., MD, Mehran, Roxana, MD, Dangas, George D., MD, PhD, Ohman, E. Magnus, MD, Witzenbichler, Bernhard, MD, Zhang, Yiran, MS, Parvataneni, Rupa, MS, Stone, Gregg W., MD

“…The association between anemia at admission and adverse outcomes in patients with acute coronary syndromes (ACS) has been incompletely studied. Anemia was…”
Get full text

Comparison of Outcomes and Prognosis of Patients With versus Without Newly Diagnosed Diabetes Mellitus After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (The HORIZONS-AMI Study) by Ertelt, Konstanze, MD, Brener, Sorin J., MD, Mehran, Roxana, MD, Ben-Yehuda, Ori, MD, McAndrew, Thomas, PhD, Stone, Gregg W., MD

“…A history of diabetes mellitus (DM) is an independent predictor for adverse events in patients with acute STEMI undergoing primary percutaneous coronary…”
Get full text

Impact of Atrial Fibrillation in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] Trial) by Rene, A. Garvey, MD, Généreux, Philippe, MD, Ezekowitz, Michael, MD, DPhil, Kirtane, Ajay J., MD, SM, Xu, Ke, PhD, Mehran, Roxana, MD, Brener, Sorin J., MD, Stone, Gregg W., MD

“…Atrial fibrillation (AF) has been associated with worse outcomes after primary percutaneous coronary intervention (PCI) for acute myocardial infarction. The…”
Get full text

Reply by Giustino, Gennaro, MD, Mehran, Roxana, MD

Get full text

Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions by Mehran, Roxana, MD, Claessen, Bimmer E., MD, Godino, Cosmo, MD, Dangas, George D., MD, PhD, Obunai, Kotaro, MD, Kanwal, Sunil, MD, Carlino, Mauro, MD, Henriques, José P.S., MD, PhD, Di Mario, Carlo, MD, Kim, Young-Hak, MD, Park, Seung-Jung, MD, Stone, Gregg W., MD, Leon, Martin B., MD, Moses, Jeffrey W., MD, Colombo, Antonio, MD

“…Objectives The aim of this study was to evaluate long-term clinical outcomes after percutaneous coronary intervention (PCI) for chronic total occlusions (CTO)…”
Get full text

Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI by Angiolillo, Dominick J., MD, PhD, Franchi, Francesco, MD, Waksman, Ron, MD, Sweeny, Joseph M., MD, Raveendran, Ganesh, MD, Teng, Renli, PhD, Zhao, Yonggang, PhD, Carlson, Glenn, MD, Khan, Naeem, MD, Mehran, Roxana, MD

“…Abstract Background Many low-risk acute coronary syndrome (ACS) patients are not pre-treated with a P2Y12 receptor inhibitor, and percutaneous coronary…”
Get full text